A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

NCT01859923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Multidrug Resistant Tuberculosis

Interventions

DRUG: Delamanid
DRUG: Delamanid Pediatric Formulation (DPF)
DRUG: Optimized Background Regimen (OBR)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.